Lisata Therapeutics, INC Form 4 insider transactions

Lisata Therapeutics' President & CEO, David J. Mazzo, was granted 81,000 restricted stock awards and 40,000 stock options, while also selling 41,096 shares to cover tax liabilities.

Lisata Therapeutics' SVP James Nisco reported the grant of restricted stock and stock options, alongside tax-related share dispositions.

Lisata Therapeutics' SVP, Tariq Imam, acquired 15,000 restricted stock awards and 7,000 stock options, while also disposing of shares for tax liabilities.

Kristen K. Buck, EVP, R&D and CMO of Lisata Therapeutics, reported the acquisition of restricted stock and stock options, alongside shares withheld for tax liabilities.

Lisata Therapeutics Director Steven M. Klosk was granted 30,456 restricted stock units, increasing his beneficial ownership.

Lisata Therapeutics Director Heidi Henson was granted 30,456 restricted stock units, aligning her interests with shareholders.

Lisata Therapeutics Director Cynthia Louise Flowers was granted 30,456 restricted stock units, which are set to vest on January 9, 2027.

Lisata Therapeutics Director Gregory B. Brown was granted 30,456 restricted stock units, vesting on January 9, 2027.

Lisata Therapeutics Director Mohammad Azab was granted 30,456 restricted stock units, vesting in January 2027.

James Nisco, SVP, Fin/Treas, Chief Actg Off of Lisata Therapeutics, reports acquisition of restricted stock and stock options, as well as disposals to cover tax liabilities.

Kristen K. Buck, EVP, R&D and CMO of Lisata Therapeutics, reports acquisition of restricted stock and disposition of shares to cover tax liabilities.

David Mazzo, CEO of Lisata Therapeutics, reports acquisition of restricted stock and stock options, as well as shares withheld for tax liabilities.

Director Steven M. Klosk reports acquisition of 15,789 restricted stock units in Lisata Therapeutics, vesting on January 9, 2026.

Director Gregory B. Brown reports acquisition of restricted stock units and changes in beneficial ownership of Lisata Therapeutics, Inc. stock.

Director Heidi Henson reports acquisition of restricted stock units and adjustments to beneficial ownership in Lisata Therapeutics.

Cynthia Louise Flowers, a director at Lisata Therapeutics, acquired 15,789 restricted stock units, which will vest on January 9, 2026.

Director Mohammad Azab of Lisata Therapeutics reported the acquisition of 15,789 restricted stock units and the holding of 74,469 shares.

EVP, R&D and CMO of Lisata Therapeutics, Kristen K. Buck, reports acquisition of 15,000 shares and disposition of 6,363 shares for tax liabilities.

James Nisco, SVP, Fin/Treas, Chief Actg Off of Lisata Therapeutics, reports acquisition of shares through performance-based stock units and withholding of shares for tax liability.

David Mazzo, CEO of Lisata Therapeutics, reports acquisition and disposal of common stock due to vesting of performance-based stock units and tax liability coverage.